The Efficacy of LPPRP in the Treatment of Chondromalacia Patella (LPPRP)
Chondromalacia Patellae
About this trial
This is an interventional treatment trial for Chondromalacia Patellae focused on measuring Chondromalacia Patellae, leukocyte-poor platelet-rich plasma, magnetic resonance imaging
Eligibility Criteria
Inclusion Criteria: Chondromalasia Patella stage 2 and above in MRI requested from patients with chronic pain around the patella, who have increased pain in at least one of the activities that carry loads while the knee is flexed (squatting, stepping, running, jumping, jumping) after physical examination and clinical evaluation Patients with VAS 3 and above Patients over 18 years of age Patients without any deformity in the lower extremity Exclusion Criteria: Coagulopathy and/or thrombocytopenia Cardiovascular instability or severe disease condition Presence of systemic infection or malignancy Pregnancy Intra-articular injection in the last 6 months Stage 3 and above meniscopathy in MRI Evidence or suspicion of rupture of the anterior cruciate ligament on MRI
Sites / Locations
- Health Sciences University, Kayseri Medicine Faculty
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Control Group
LP-PRP Group
First group (14 people): 4-weeks home exercise program will be given to control group. The exercise program includes quadriceps isometric exercises (holding for 10 seconds, 20 reps), straight leg raises (20 reps holding for 6 seconds), and semi-squatting exercises (20 reps), hip flexors, hamstring and iliotibial band stretching exercises (20-repetitions), strengthening exercises for hip abductors and adductors (holding for 6 seconds with 20 repetitions). These exercises were said to be performed for 30 minutes, once a day, every day for 4 weeks.
Second group (14 people): LP-PRP injection and 4-week exercise program will be applied by targeting the suprapatellar bursa. The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.